|
WO2005010044A2
(en)
|
2003-07-08 |
2005-02-03 |
Genentech, Inc. |
Il-17 a/f heterologous polypeptides and therapeutic uses thereof
|
|
WO2010048415A1
(en)
*
|
2008-10-22 |
2010-04-29 |
Cedars-Sinai Medical Center |
Methods of using jak3 genetic variants to diagnose and predict crohn's disease
|
|
AU2005314089B2
(en)
*
|
2004-12-08 |
2011-03-03 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of Crohn's disease
|
|
US7910703B2
(en)
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
WO2007147019A2
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc. |
Il-17 and il-23 antagonists and methods of using the same
|
|
CN101646690B
(zh)
|
2006-08-11 |
2013-10-23 |
默沙东公司 |
抗il-17a抗体
|
|
US8414897B1
(en)
|
2006-10-02 |
2013-04-09 |
The Uab Research Foundation |
Pathway for Th-17 cell development and methods utilizing same
|
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Ｉｌ-２３拮抗劑於治療感染之用途
|
|
US20100021917A1
(en)
*
|
2007-02-14 |
2010-01-28 |
Cedars-Sinai Medical Center |
Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
|
|
SG178804A1
(en)
|
2007-02-23 |
2012-03-29 |
Schering Corp |
Engineered anti-il-23p19 antibodies
|
|
DK2426144T3
(en)
|
2007-02-23 |
2019-01-07 |
Merck Sharp & Dohme |
Manipulated Anti-IL-23P19 Antibodies
|
|
US20100190162A1
(en)
*
|
2007-02-26 |
2010-07-29 |
Cedars-Sinai Medical Center |
Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
|
|
CA2679400A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Schering Corporation |
Combination therapy for treatment of immune disorders
|
|
US20100055700A1
(en)
*
|
2007-02-28 |
2010-03-04 |
Cedars-Sinai Medical Center |
Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
|
|
WO2010039931A2
(en)
*
|
2008-10-01 |
2010-04-08 |
Cedars-Sinai Medical Center |
Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
|
|
WO2008137762A2
(en)
*
|
2007-05-04 |
2008-11-13 |
Cedars-Sinai Medical Center |
Methods of diagnosis and treatment of crohn's disease
|
|
US20100015156A1
(en)
*
|
2007-03-06 |
2010-01-21 |
Cedars-Sinai Medical Center |
Diagnosis of inflammatory bowel disease in children
|
|
US8486640B2
(en)
|
2007-03-21 |
2013-07-16 |
Cedars-Sinai Medical Center |
Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
|
|
WO2008134569A2
(en)
*
|
2007-04-26 |
2008-11-06 |
Cedars-Sinai Medical Center |
Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
|
|
ES2465223T3
(es)
*
|
2007-04-27 |
2014-06-05 |
Zymogenetics, Inc. |
Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
|
|
US9305137B1
(en)
|
2007-05-18 |
2016-04-05 |
Cedars-Sinai Medical Center |
Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
|
|
EP3246045B1
(en)
*
|
2007-07-26 |
2025-09-03 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
|
US20100203009A1
(en)
*
|
2007-10-02 |
2010-08-12 |
The Uab Research Foundation |
Pathway for Th-17 Cell Development and Methods Utilizing Same
|
|
WO2009082624A2
(en)
*
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
ES2456296T3
(es)
*
|
2008-03-27 |
2014-04-21 |
Zymogenetics, Inc. |
Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
|
|
CA2721713C
(en)
|
2008-05-05 |
2019-07-09 |
Novimmune Sa |
Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
WO2010019565A2
(en)
*
|
2008-08-12 |
2010-02-18 |
Medlmmune, Llc |
Anti-ephrin b2 antibodies and their use in treatment of disease
|
|
EP2331078B1
(en)
|
2008-08-27 |
2012-09-19 |
Merck Sharp & Dohme Corp. |
Lyophilized formulations of engineered anti-il-23p19 antibodies
|
|
US8790642B2
(en)
*
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
AU2009314111A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
BetaGI-IgG intron for enhanced anti-IGF1 R expression
|
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
|
WO2010062960A2
(en)
|
2008-11-26 |
2010-06-03 |
Cedars-Sinai Medical Center |
METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
|
|
MX2011006549A
(es)
|
2008-12-19 |
2011-07-20 |
Schering Corp |
Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
|
|
WO2010075579A2
(en)
|
2008-12-24 |
2010-07-01 |
Cedars-Sinai Medical Center |
Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
|
|
EP2427203B1
(en)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f antibodies and use thereof
|
|
KR101741859B1
(ko)
|
2009-06-22 |
2017-06-15 |
암젠 인크 |
화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
|
|
SI3660032T1
(sl)
|
2009-06-25 |
2026-02-27 |
Amgen Inc. |
Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
AU2010291985B2
(en)
|
2009-09-14 |
2016-05-05 |
The Regents Of The University Of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
|
JO3244B1
(ar)
*
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
JP5922025B2
(ja)
*
|
2009-10-30 |
2016-05-25 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｉｌ−１７ａ拮抗物質
|
|
GB201013975D0
(en)
|
2010-08-20 |
2010-10-06 |
Imp Innovations Ltd |
Method of treating desease
|
|
US9045536B2
(en)
|
2009-12-23 |
2015-06-02 |
Merck Sharp & Dohme Corp. |
Cell line 3M
|
|
RS59830B1
(sr)
|
2010-03-01 |
2020-02-28 |
Bayer Healthcare Llc |
Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
|
|
US20130011406A1
(en)
*
|
2010-03-26 |
2013-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
|
SG190006A1
(en)
|
2010-11-04 |
2013-06-28 |
Boehringer Ingelheim Int |
Anti-il-23 antibodies
|
|
EP3763740A1
(en)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
RS57024B1
(sr)
|
2011-06-10 |
2018-05-31 |
Medimmune Ltd |
Anti-pseudomonas psl vezujući molekuli i njihova upotreba
|
|
USRE49026E1
(en)
|
2011-06-14 |
2022-04-12 |
Medical Diagnostic Laboratories, Llc |
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
|
|
US8946150B2
(en)
|
2011-06-14 |
2015-02-03 |
Medical Diagnostic Laboratories, LLC. |
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
|
|
EP2583979B1
(en)
*
|
2011-10-19 |
2015-12-16 |
Effimune |
Methods to prepare antibodies directed against p19 subunit of human IL-23
|
|
US10597439B2
(en)
|
2011-11-07 |
2020-03-24 |
Medimmune Limited |
Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
|
|
WO2013116682A1
(en)
|
2012-02-02 |
2013-08-08 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating il-17
|
|
CN104507497B
(zh)
|
2012-05-03 |
2018-10-19 |
勃林格殷格翰国际有限公司 |
抗IL-23p19抗体
|
|
ES2711554T3
(es)
*
|
2012-05-22 |
2019-05-06 |
Bristol Myers Squibb Co |
Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
|
|
SG11201407806YA
(en)
*
|
2012-05-31 |
2014-12-30 |
Agency Science Tech & Res |
Mixed multifunctional metal affinity surfaces for reducing aggregate content in protein preparations field
|
|
EP2866833B1
(en)
|
2012-06-27 |
2019-05-15 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human il-23 antibodies
|
|
CN104812775B
(zh)
|
2012-07-25 |
2019-05-03 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
CN116003600A
(zh)
*
|
2012-10-05 |
2023-04-25 |
卡德门企业有限公司 |
人抗vegfr-2/kdr抗体
|
|
US20150238601A1
(en)
*
|
2012-10-05 |
2015-08-27 |
Kadmon Corporation, Llc |
Treatment of ocular disorders
|
|
US9273093B2
(en)
|
2012-10-11 |
2016-03-01 |
Protagonist Therapeutics, Inc. |
α4β7 peptide dimer antagonists
|
|
US10526384B2
(en)
|
2012-11-19 |
2020-01-07 |
Pieris Pharmaceuticals Gmbh |
Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
KR102236829B1
(ko)
|
2013-03-15 |
2021-04-07 |
프로타고니스트 테라퓨틱스, 인코포레이티드 |
헵시딘 유사체 및 이의 용도
|
|
CN105307675A
(zh)
|
2013-03-15 |
2016-02-03 |
美国安进公司 |
使用抗il23抗体治疗克罗恩氏病的方法
|
|
CN105209064A
(zh)
|
2013-03-15 |
2015-12-30 |
美国安进公司 |
使用抗il-23抗体治疗银屑病的方法
|
|
KR20230109779A
(ko)
|
2013-03-27 |
2023-07-20 |
세다르스-신나이 메디칼 센터 |
Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
|
|
EP4105236A1
(en)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
AU2015258863B2
(en)
|
2014-05-16 |
2019-10-24 |
Protagonist Therapeutics, Inc. |
Alpha4beta7 integrin thioether peptide antagonists
|
|
CA2949405C
(en)
|
2014-05-22 |
2023-08-01 |
Pieris Pharmaceuticals Gmbh |
Novel specific-binding polypeptides and uses thereof
|
|
EP3145543A4
(en)
|
2014-05-23 |
2017-12-13 |
Celldex Therapeutics, Inc. |
Treatment of eosinophil or mast cell related disorders
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
WO2016009451A2
(en)
*
|
2014-07-14 |
2016-01-21 |
Gennova Biopharmaceuticals Limited |
A novel process for purification of rhu-gcsf
|
|
AU2015289642B2
(en)
*
|
2014-07-17 |
2021-02-25 |
Protagonist Therapeutics, Inc. |
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
WO2016014775A1
(en)
|
2014-07-24 |
2016-01-28 |
Boehringer Ingelheim International Gmbh |
Biomarkers useful in the treatment of il-23a related diseases
|
|
AR101753A1
(es)
|
2014-09-03 |
2017-01-11 |
Boehringer Ingelheim Int |
COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
|
|
EP3201217A4
(en)
|
2014-10-01 |
2018-07-18 |
Protagonist Therapeutics Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
|
WO2016054411A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
|
AR102417A1
(es)
|
2014-11-05 |
2017-03-01 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-tnf- / anti-il-23
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
SG10202103879YA
(en)
|
2015-02-04 |
2021-05-28 |
Boehringer Ingelheim Int |
Methods of treating inflammatory diseases
|
|
WO2016138312A2
(en)
*
|
2015-02-25 |
2016-09-01 |
Vanderbilt University |
Antibody-mediated neutralization of marburg virus
|
|
HK1247622A1
(zh)
|
2015-03-02 |
2018-09-28 |
180 Therapeutics Lp |
利用il-33拮抗剂来治疗局部纤维化的方法
|
|
MX2017013156A
(es)
*
|
2015-04-14 |
2018-02-21 |
Boehringer Ingelheim Int |
Metodos para tratar enfermedades.
|
|
CN107921127B
(zh)
*
|
2015-05-22 |
2022-04-08 |
纪念斯隆-凯特琳癌症中心 |
对于prame肽具有特异性的t细胞受体样抗体
|
|
MA41010B1
(fr)
*
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
HK1258292A1
(zh)
|
2015-09-17 |
2019-11-08 |
Amgen Inc. |
使用il23途径生物标志物预测il23拮抗剂的临床应答
|
|
CN108368167B
(zh)
|
2015-11-27 |
2023-09-05 |
杰特有限公司 |
Cd131结合蛋白及其应用
|
|
AU2016379157A1
(en)
|
2015-12-22 |
2018-06-21 |
Amgen Inc. |
CCL20 as a predictor of clinical response to IL23-antagonists
|
|
WO2017117411A1
(en)
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
KR20180127416A
(ko)
|
2016-03-17 |
2018-11-28 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
|
EP3432906A4
(en)
|
2016-03-23 |
2020-04-01 |
Protagonist Therapeutics, Inc. |
METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
|
|
WO2017205820A1
(en)
*
|
2016-05-27 |
2017-11-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Affinity matured broad spectrum antibodies to hepatitis c virus
|
|
US9611297B1
(en)
*
|
2016-08-26 |
2017-04-04 |
Thrasos Therapeutics Inc. |
Compositions and methods for the treatment of cast nephropathy and related conditions
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
US10278957B2
(en)
|
2017-09-11 |
2019-05-07 |
Protagonist Therapeutics, Inc. |
Opioid agonist peptides and uses thereof
|
|
EP3749345A4
(en)
|
2018-02-08 |
2022-04-06 |
Protagonist Therapeutics, Inc. |
CONJUGATED HEPCIDIN MIMETICS
|
|
EP3773717A4
(en)
*
|
2018-03-29 |
2022-05-11 |
REMD Biotherapeutics, Inc. |
TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A).
|
|
TW202019948A
(zh)
|
2018-07-12 |
2020-06-01 |
美商領導醫療有限公司 |
介白素-23受體之肽抑制劑及其治療發炎疾病之用途
|
|
CA3105598A1
(en)
|
2018-07-13 |
2020-01-16 |
Carl GOMMOLL |
Treating ulcerative colitis with brazikumab
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
MX2022000397A
(es)
|
2019-07-10 |
2022-04-25 |
Protagonist Therapeutics Inc |
Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
|
|
TW202123965A
(zh)
|
2019-09-09 |
2021-07-01 |
德商百靈佳殷格翰國際股份有限公司 |
抗-il-23p19抗體調配物
|
|
EP4077378A1
(en)
*
|
2019-12-20 |
2022-10-26 |
NovaRock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
|
CN118063554A
(zh)
|
2020-01-15 |
2024-05-24 |
詹森生物科技公司 |
介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
|
|
KR20220141808A
(ko)
|
2020-01-15 |
2022-10-20 |
얀센 바이오테크 인코포레이티드 |
인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
|
|
US20220206001A1
(en)
*
|
2020-10-22 |
2022-06-30 |
Twist Bioscience Corporation |
Methods and systems for detecting coronavirus
|
|
KR20230110570A
(ko)
|
2020-11-20 |
2023-07-24 |
얀센 파마슈티카 엔.브이. |
인터류킨-23 수용체의 펩티드 억제제의 조성물
|
|
TW202330013A
(zh)
|
2021-07-14 |
2023-08-01 |
美商健生生物科技公司 |
介白素－２３受體之脂化肽抑制劑
|
|
WO2023122211A2
(en)
*
|
2021-12-21 |
2023-06-29 |
Duke University |
Coronavirus antibodies and uses thereof
|
|
EP4626930A2
(en)
*
|
2022-12-02 |
2025-10-08 |
Jecho Laboratories, Inc. |
Anti-mesothelin bispecific antibodies and methods of use
|
|
AU2024353756A1
(en)
*
|
2023-09-27 |
2026-05-07 |
Samsung Bioepis Co., Ltd. |
Stable liquid formulation of anti-il-17 antibody
|
|
WO2026058045A1
(en)
|
2024-09-12 |
2026-03-19 |
Takeda Pharmaceutical Company Limited |
Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
|